Anti-Coagulants - Portugal

Portugal

In Portugal, the Anti-Coagulants market is expected to experience significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach US$69.17m.
This growth is anticipated to continue, with an annual growth rate (CAGR 2024-2029) of 7.74%.
By 2029, the market volume is expected to reach US$100.40m.
When comparing the global market, it is worth noting that United States is projected to generate the highest revenue in the Anti-Coagulants market.
In 2024, the revenue from this market United States is estimated to be US$16,740.00m.
Portugal is experiencing a growing demand for novel oral anticoagulants as an alternative to traditional warfarin therapy.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Portugal has seen significant growth over the past few years.

Customer preferences: Patients suffering from cardiovascular diseases in Portugal prefer anti-coagulants due to their effectiveness in preventing blood clots. Additionally, the aging population in the country has also contributed to the growth of the market as they are more prone to these diseases.

Trends in the market: There has been a shift towards the use of direct oral anticoagulants (DOACs) in Portugal. This is due to their ease of use and reduced risk of bleeding compared to traditional anti-coagulants like warfarin. The market for DOACs has been growing rapidly as more patients are prescribed these drugs. Furthermore, there has been an increase in the number of patients diagnosed with atrial fibrillation, which has further driven the growth of the market.

Local special circumstances: The healthcare system in Portugal is publicly funded, which means that the government plays a significant role in regulating the market. The government has been promoting the use of generic drugs to reduce healthcare costs, which has resulted in increased competition in the market. Additionally, there has been a rise in the number of pharmacies in the country, which has made it easier for patients to access these drugs.

Underlying macroeconomic factors: The Portuguese economy has been recovering from the global financial crisis, which has resulted in increased healthcare spending. This has provided a boost to the anti-coagulants market as more patients are able to afford these drugs. Additionally, Portugal is a popular retirement destination for Europeans, which has resulted in an aging population and an increase in the number of patients suffering from cardiovascular diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.